EVOK Evoke Pharma, Inc: Rasio rega marang prakiraan pendapatan

Lambang korporat lan logo Evoke Pharma Inc. (EVOK)

Evoke Pharma, Inc. (EVOK) maintains a niche in gastroparesis therapy through its convenient nasal drug formulations. The projected P/S value in the time series on the GURU.Markets chart clearly demonstrates an overvaluation of future revenues, where the 1.30 level captures the current state. Stable demand ensures cash flow, however, reliance on a single product and patent risks necessitate caution.

Evoke Pharma Inc. - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep EVOK (periode 04.07.2022 - 27.12.2025)

Rincian metrik keuangan lan pasar Evoke Pharma, Inc. (EVOK)

- data kapitalisasi saham perusahaan:
Ringkesan analisis perusahaan:Evoke Pharma Inc. EVOK
Produk asli Evoke Pharma Inc

The forward P/S is calculated as the ratio of market capitalization to expected revenue, allowing for an assessment of the asset's valuation relative to future cash flows. The stability of supply chains for gastroparesis treatments reduces operational risks for Evoke Pharma, Inc. (EVOK), making the expected P/S value a reliable indicator for determining whether the stock is overvalued or if the company possesses acquisition potential.